STAT3 paradoxically stimulates β-catenin expression but inhibits β-catenin function

International Journal of Experimental Pathology

Volumn 95, Issue 6, 2014, Pages 392-400

  Ibrahem, Salih ^a   Al Ghamdi, Saleh ^a   Baloch, Kanwal ^a   Muhammad, Belal ^a   Fadhil, Wakkas ^a   Jackson, Darryl ^a   Nateri, Abdolrahman S ^a   Ilyas, Mohammad ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Colorectal cancer; Oncogene interaction; STAT3 signalling; Wnt signalling

Indexed keywords

BETA CATENIN; INTERLEUKIN 6; MESSENGER RNA; PROTEASOME; STAT3 PROTEIN; CTNNB1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL MOTILITY; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; STIMULATION; WNT SIGNALING PATHWAY; APOPTOSIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; BETA CATENIN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HT29 CELLS; HUMANS; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; WNT SIGNALING PATHWAY;

EID: 84921461169     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12102     Document Type: Article

References (39)

1. Ahmed M.A., Jackson D., Seth R. et al. (2010) CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation. Inflamm. Bowel Dis. 16, 795-803.
2. Albasri A., Al-Ghamdi S., Fadhil W. et al. (2011) Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Oncogene 30, 2997-3002.
3. Albuquerque C., Breukel C., van der Luijt R. et al. (2002) The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. Hum. Mol. Genet. 11, 1549-1560.
4. Anand M., Lai R. & Gelebart P. (2010) beta-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 96, 253-261.
5. Armanious H., Gelebart P., Mackey J. et al. (2010) STAT3 upregulates the protein expression and transcriptional activity of beta-catenin in breast cancer. Int. J. Clin. Exp. Pathol. 3, 654-664.
6. Brocke-Heidrich K., Kretzschmar A.K., Pfeifer G. et al. (2004) Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 103, 242-251.
7. Bromberg J.F., Wrzeszczynska M.H., Devgan G. et al. (1999) Stat3 as an oncogene. Cell 98, 295-303.
8. Cheng G.Z., Zhang W.Z., Sun M. et al. (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J. Biol. Chem. 283, 14665-14673.
9. Conacci-Sorrell M.E., Ben-Yedidia T., Shtutman M. et al. (2002) Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev. 16, 2058-2072.
10. da Costa L.T., He T.C., Yu J. et al. (1999) CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. Oncogene 18, 5010-5014.
11. Dvory-Sobol H., Sagiv E., Liberman E. et al. (2007) Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Cancer 109, 188-197.
12. Fadhil W., Ibrahem S., Seth R. et al. (2010) Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue. J. Clin. Pathol. 63, 134-140.
13. Fearon E.R. & Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
14. Felsher D.W. (2008) Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res. 68, 3081-3086; discussion 3086.
15. Greaves M. & Maley C.C. (2012) Clonal evolution in cancer. Nature 481, 306-313.
16. He T.C., Sparks A.B., Rago C. et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512.
17. Ilyas M., Tomlinson I.P., Rowan A. et al. (1997) Beta-catenin mutations in cell lines established from human colorectal cancers. Proc. Natl Acad. Sci. USA 94, 10330-10334.
18. Ilyas M., Straub J., Tomlinson I.P. et al. (1999) Genetic pathways in colorectal and other cancers. Eur. J. Cancer 35, 1986-2002.
19. Janssen K.P., Alberici P., Fsihi H. et al. (2006) APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 131, 1096-1109.
20. Kawada M., Seno H., Uenoyama Y. et al. (2006) Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer. Cancer Res. 66, 2913-2917.
21. Kusaba T., Nakayama T., Yamazumi K. et al. (2005) Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J. Clin. Pathol. 58, 833-838.
22. Mann B., Gelos M., Siedow A. et al. (1999) Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl Acad. Sci. USA 96, 1603-1608.
23. Mologni L., Dekhil H., Ceccon M. et al. (2010) Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res. 70, 7253-7263.
24. Morikawa T., Baba Y., Yamauchi M. et al. (2011) STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin. Cancer Res. 17, 1452-1462.
25. Morin P.J., Sparks A.B., Korinek V. et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275, 1787-1790.
26. Musteanu M., Blaas L., Mair M. et al. (2009) Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138, 1003-1011.e1001-e1005.
27. Rivat C., De Wever O., Bruyneel E. et al. (2004) Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes. Oncogene 23, 3317-3327.
28. Rowan A.J., Lamlum H., Ilyas M. et al. (2000) APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits". Proc. Natl Acad. Sci. USA 97, 3352-3357.
29. Simon A.R., Vikis H.G., Stewart S. et al. (2000) Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 290, 144-147.
30. Stewart B.W. & Kleihues P. (2003) World Cancer Report. Lyon, France: IARC Press, WHO.
31. Tetsu O. & McCormick F. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426.
32. Turkson J., Bowman T., Garcia R. et al. (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18, 2545-2552.
33. Ullenhag G.J., Mukherjee A., Watson N.F. et al. (2007) Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res. 13, 5070-5075.
34. Walker R.A. (2006) Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology 49, 406-410.
35. Wilson C.L., Heppner K.J., Labosky P.A. et al. (1997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl Acad. Sci. USA 94, 1402-1407.
36. Yan S., Zhou C., Zhang W. et al. (2008) beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 271, 85-97.
37. Yang J. & Stark G.R. (2008) Roles of unphosphorylated STATs in signaling. Cell Res. 18, 443-451.
38. Yu H., Pardoll D. & Jove R. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809.
39. Zhang T., Otevrel T., Gao Z. et al. (2001) Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 61, 8664-8667.